Premium
Lexeo Therapeutics Inc (LXEO)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Actionnaire | Type | Détenues (Réel) | % en Circulation | Valeur Marchande | Date de Reporte |
|---|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | Institution | 6 184 134 | 7,88% | US$ 27,52M | 2026-03-31 |
| Suvretta Capital Management, LLC | Institution | 5 674 778 | 7,23% | US$ 25,25M | 2026-04-06 |
| BlackRock, Inc. | Institution | 5 110 871 | 6,51% | US$ 22,74M | 2026-03-31 |
| Affinity Asset Advisors, LLC | Institution | 5 050 211 | 6,43% | US$ 22,47M | 2026-03-31 |
| RA Capital Management, L.P. | Institution | 5 000 000 | 6,37% | US$ 22,25M | 2026-03-31 |
| RA Capital Healthcare Fund, L.P. | Institution | 5 000 000 | 6,37% | US$ 22,25M | 2025-10-20 |
| Averill Master Fund, Ltd. | Institution | 4 827 730 | 6,15% | US$ 21,48M | 2026-04-06 |
| Vestal Point Capital, LP | Institution | 4 475 000 | 5,70% | US$ 19,91M | 2026-03-31 |
| Frazier Life Sciences Management, LP | Institution | 4 424 725 | 5,64% | US$ 19,69M | 2026-03-31 |
| Affinity Healthcare Fund, LP | Institution | 4 350 358 | 5,54% | US$ 19,36M | 2026-01-22 |
| Paradigm BioCapital International Fund Ltd. | Institution | 4 207 159 | 5,36% | US$ 18,72M | 2025-12-31 |
| Citadel Advisors LLC | Institution | 3 834 999 | 4,88% | US$ 17,07M | 2026-03-31 |
| Frazier Life Sciences Public Fund, L.P. | Institution | 3 698 271 | 4,71% | US$ 16,46M | 2025-12-31 |
| OrbiMed Advisors LLC | Institution | 3 602 450 | 4,59% | US$ 16,03M | 2026-03-31 |
| Longitude Capital Management Co., LLC | Institution | 2 765 381 | 3,52% | US$ 12,31M | 2025-09-30 |
| Longitude Venture Partners IV, L.P. | Institution | 2 765 381 | 3,52% | US$ 12,31M | 2025-09-30 |
| Woodline Partners LP | Institution | 2 750 532 | 3,50% | US$ 12,24M | 2026-03-31 |
| Janus Henderson Biotech Innovation Master Fund Limited | Institution | 2 683 874 | 3,42% | US$ 11,94M | 2025-03-31 |
| Mizuho Financial Group, Inc. | Institution | 2 203 631 | 2,81% | US$ 9,81M | 2025-03-31 |
| Integrated Core Strategies (US) LLC | Institution | 2 065 700 | 2,63% | US$ 9,19M | 2025-09-30 |
| Avoro Capital Advisors LLC | Institution | 1 875 000 | 2,39% | US$ 8,34M | 2026-03-31 |
| Point72 Asset Management, L.P. | Institution | 1 680 449 | 2,14% | US$ 7,48M | 2026-03-31 |
| Millennium Management LLC | Institution | 1 612 780 | 2,05% | US$ 7,18M | 2026-03-31 |
| Balyasny Asset Management L.P. | Institution | 1 589 585 | 2,02% | US$ 7,07M | 2026-03-31 |
| ADAR1 Capital Management, LLC | Institution | 1 467 350 | 1,87% | US$ 6,53M | 2026-03-31 |
| Nantahala Capital Management, LLC | Institution | 1 200 000 | 1,53% | US$ 5,34M | 2026-03-31 |
| 683 Capital Management, LLC | Institution | 1 200 000 | 1,53% | US$ 5,34M | 2026-03-31 |
| Octagon Capital Advisors LP | Institution | 1 100 000 | 1,40% | US$ 4,90M | 2026-03-31 |
| Spruce Street Capital LP | Institution | 928 593 | 1,18% | US$ 4,13M | 2026-03-31 |
| Blackstone Alternative Asset Management L.P. | Institution | 904 959 | 1,15% | US$ 4,03M | 2026-03-31 |
| Frazier Life Sciences Public Overage Fund, L.P. | Institution | 624 804 | 0,80% | US$ 2,78M | 2025-05-28 |
| Ikarian Capital, LLC | Institution | 513 011 | 0,65% | US$ 2,28M | 2026-03-31 |
| Atlas Diversified Master Fund, Ltd. | Institution | 454 440 | 0,58% | US$ 2,02M | 2026-03-31 |
| Frazier Life Sciences XII, L.P. | Institution | 406 246 | 0,52% | US$ 1,81M | 2025-12-31 |
| Dafna Capital Management, LLC | Institution | 377 059 | 0,48% | US$ 1,68M | 2026-03-31 |
| Morgan Stanley | Institution | 283 080 | 0,36% | US$ 1,26M | 2026-03-31 |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
